Stifel Nicolaus Raises Cipher Pharmaceuticals (TSE:CPH) Price Target to C$19.00

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its price target boosted by Stifel Nicolaus from C$17.00 to C$19.00 in a research note released on Thursday morning, BayStreet.CA reports.

CPH has been the subject of a number of other reports. Leede Financial lowered shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th. Stifel Canada upgraded Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th.

Cipher Pharmaceuticals Price Performance

CPH opened at C$16.52 on Thursday. The company has a quick ratio of 2.67, a current ratio of 11.18 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is C$16.45 and its 200 day moving average price is C$11.80. Cipher Pharmaceuticals has a fifty-two week low of C$4.30 and a fifty-two week high of C$19.69. The firm has a market cap of C$422.75 million, a price-to-earnings ratio of 13.32 and a beta of 1.20.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings results on Thursday, August 8th. The company reported C$0.16 earnings per share for the quarter, topping analysts’ consensus estimates of C$0.15 by C$0.01. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The business had revenue of C$7.26 million for the quarter, compared to analysts’ expectations of C$7.52 million. As a group, sell-side analysts expect that Cipher Pharmaceuticals will post 1.6472868 earnings per share for the current year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.